Trial Profile

A double-blind, prospective, randomized phase II/III trial of VYD-2311 for prevention of COVID-2019 infections

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 06 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jan 2026 According to an Invivyd media release, company has announced the plan to initiate this Phase 2 study evaluating monoclonal antibody VYD2311 in individuals with Long COVID or COVID vaccine injury by mid-2026.
22 Oct 2025 New trial record
04 Sep 2025 According to an Invivyd media release, this study has a randomized, placebo-controlled design with more than 100 patients per arm, powered to generate definitive, reliable evidence.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com